-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 L+2JVCA/8yIg27+q9D7XedWasWmnCzswsSVF9Lamk1s4ym9RyvYZHXs4iHvojmVX
 m8IqZqjTNE9vIB9wTVjbAQ==

<SEC-DOCUMENT>0001104659-08-040962.txt : 20080619
<SEC-HEADER>0001104659-08-040962.hdr.sgml : 20080619
<ACCEPTANCE-DATETIME>20080619162822
ACCESSION NUMBER:		0001104659-08-040962
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20080430
FILED AS OF DATE:		20080619
DATE AS OF CHANGE:		20080619

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTERLEUKIN GENETICS INC
		CENTRAL INDEX KEY:			0001037649
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				943123681
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		135 BEAVER ST
		CITY:			WATHAM
		STATE:			MA
		ZIP:			02452
		BUSINESS PHONE:		1-781-398-0700

	MAIL ADDRESS:	
		STREET 1:		135 BEAVER ST
		CITY:			WATHAM
		STATE:			MA
		ZIP:			02452

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MEDICAL SCIENCE SYSTEMS INC
		DATE OF NAME CHANGE:	19971003

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Lurier Eliot M
		CENTRAL INDEX KEY:			0001438037

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32715
		FILM NUMBER:		08908052

	BUSINESS ADDRESS:	
		BUSINESS PHONE:		(781) 398-0700

	MAIL ADDRESS:	
		STREET 1:		C/O INTERLEUKIN GENETICS, INC.
		STREET 2:		135 BEAVER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02452
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>a4.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2008-04-30</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001037649</issuerCik>
        <issuerName>INTERLEUKIN GENETICS INC</issuerName>
        <issuerTradingSymbol>ILI</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001438037</rptOwnerCik>
            <rptOwnerName>Lurier Eliot M</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O INTERLEUKIN GENETICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>135 BEAVER STREET</rptOwnerStreet2>
            <rptOwnerCity>WALTHAM</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02452</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.49</value>
                <footnoteId id="F2"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2008-04-30</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>40000</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2009-04-30</value>
            </exerciseDate>
            <expirationDate>
                <value>2018-04-30</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>40000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>40000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The option will vest in equal annual installments of 8,000 shares on each of the first five anniversaries of the grant date.</footnote>
        <footnote id="F2">This was the closing price of the issuer's common stock on AMEX on April 30, 2008.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Marianne Staniunas, Attorney-in-Fact</signatureName>
        <signatureDate>2008-06-19</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----